Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Neuraminidase inhibitors Stories

2012-04-17 02:28:46

ALBANY, N.Y., April 17, 2012 /PRNewswire/ -- AMRI (NYSE: AMRI), a leading global contract research and manufacturing organization, was selected by Biota Holdings Limited (ASX: BTA), a leading anti-infective drug development company based in Australia, to further develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. AMRI will provide these services to support a New Drug Application for laninamivir to the United States...

2012-04-11 12:10:09

The full clinical study reports of drugs that have been authorized for use in patients should be made publicly available in order to allow independent re-analysis of the benefits and risks of such drugs, according to leading international experts who base their assertions on their experience with Tamiflu (oseltamivir). Tamiflu is classed by the World Health Organization as an essential drug and many countries have stockpiled the anti-influenza drug at great expense to taxpayers. But a...

Researchers Question Effectiveness Of Tamiflu, Roche Withholds Trial Data
2012-01-18 13:35:57

A group of independent scientists has challenged the manufacturers of the anti-flu treatment Tamiflu to substantiate the treatment´s effectiveness by releasing previously withheld research data. In a recent report released by the non-profit Cochrane Collaboration, researchers stated that although Tamiflu does help relieve flu symptoms an average of 21 hours more quickly, it did not appear to reduce spread of the virus or the chances of being hospitalized for flu-related illnesses....

2012-01-18 12:58:11

Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages of clinical trial data and documents used in the process of licensing oseltamivir (Tamiflu) by national authorities, a team of researchers has raised critical questions about how well the drug works and about its reported safety profile. The new analysis shows...

2011-11-06 23:01:00

Largest study to date finds co-infection with MRSA increased death risk 8-fold; flu vaccination urged BOSTON, Nov. 7, 2011 /PRNewswire-USNewswire/ -- During the 2009 H1N1 influenza pandemic, many previously healthy children became critically ill, developing severe pneumonia and respiratory failure, sometimes fatal. The largest nationwide investigation to date of influenza in critically ill children, led by Children's Hospital Boston, found one key risk factor: Simultaneous...

2011-10-21 09:13:00

TAMPA, Fla., Oct. 21, 2011 /PRNewswire/ -- Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) The clinical trial enrolled 624 patients at 74 outpatient primary care...

2011-08-15 09:00:00

SAN DIEGO, Aug. 15, 2011 /PRNewswire/ -- NexBio announced top line data from a Phase 2 clinical trial of DAS181, an investigational drug for treatment and prophylaxis of Influenza-Like Illness (ILI) caused by all types and strains of influenza and parainfluenza viruses, including pandemic influenza strains. In a double-blind, placebo-controlled, Phase 2 trial of otherwise healthy adults infected with influenza virus, treatment with DAS181 resulted in a significant reduction in patients'...

2011-07-13 11:00:00

SILVER SPRING, Md., July 13, 2011 /PRNewswire-USNewswire/ -- When flu season arrives this fall, a liquid form of Tamiflu--the most widely used anti-viral flu medication--will be available in a new, lower concentration to reduce the possibility of medication errors. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) The change applies to the oral suspension form of Tamiflu. Oral suspension is a powder form of the prescription medication that a pharmacist mixes with water to make a...

2011-06-14 12:41:00

LISBON, Portugal, June 14, 2011 /PRNewswire/ -- Hovione announced today the international filing of its latest patent covering a new, highly efficient dry powder inhaler (DPI), XCaps. XCaps fills a void in the pulmonary inhalation market, as a device which combines high efficiency in powder dispersion with ease of use. Lung fractions in excess of 70% have been achieved, from a device which only requires two steps to inhalation and which only has two components plus a dust...

2011-06-07 13:09:00

VANCOUVER, British Columbia, June 7, 2011 /PRNewswire/ -- Abattis Biologix Corporation (CNSX: FLU) announced today they have learned that the U.S. Government has charged Dr. Charles Hensley with unlawfully importing and distributing an unapproved herbal product named, "Vira 38," in 2005. The federal indictment further charges that Dr. Hensley unlawfully credited Vira 38 with treating bird flu without FDA approval. Recently, Abattis obtained all rights, title and interest to Dr. Hensley's...